常规与延迟门静脉期MRI诊断肝细胞癌:钆塞酸二钠MRI与细胞外对比剂MRI的个体内比较
本回顾性研究纳入107例前瞻性入组的高危患者共143个病灶(118个肝细胞癌),所有患者均接受细胞外对比剂MRI及钆塞酸二钠MRI(分别采用常规门静脉期和延迟门静脉期),由两名放射科医师按LI-RADS v2018评估。钆塞酸二钠MRI采用延迟门静脉期时,LR-5诊断肝细胞癌的敏感度高于细胞外对比剂MRI和采用常规门静脉期的钆塞酸二钠MRI,特异度无显著差异。
要点
- 钆塞酸二钠MRI延迟门静脉期诊断肝细胞癌的敏感度高于细胞外对比剂MRI,特异度无显著差异。
- 钆塞酸二钠MRI常规门静脉期诊断肝细胞癌的敏感度低于细胞外对比剂MRI。
- 肝细胞癌非周边廓清表现在钆塞酸二钠MRI延迟门静脉期较细胞外对比剂MRI更常见。
核心结论
- 钆塞酸二钠MRI采用延迟门静脉期诊断肝细胞癌的敏感度高于细胞外对比剂MRI和采用常规门静脉期的钆塞酸二钠MRI,同时保持相当的特异度。
研究设计与样本
- 回顾性研究,纳入107例前瞻性入组的高危患者(平均年龄59.4岁,89名男性),共143个病灶(118个肝细胞癌),所有患者均接受细胞外对比剂MRI及钆塞酸二钠MRI(分别采用常规门静脉期和延迟门静脉期),由两名放射科医师按LI-RADS v2018评估。
关键影像表现/征象
- 肝细胞癌中,非周边廓清表现在钆塞酸二钠MRI常规门静脉期较细胞外对比剂MRI少见(R1:69.5% vs 79.7%,p=0.02;R2:66.9% vs 76.3%,p=0.02)。
- 肝细胞癌中,非周边廓清表现在钆塞酸二钠MRI延迟门静脉期较细胞外对比剂MRI多见(R1:94.1% vs 79.7%,p<0.001;R2:92.4% vs 76.3%,p<0.001)。
诊断标准与关键数值
- LR-5诊断肝细胞癌的敏感度:钆塞酸二钠MRI延迟门静脉期R1为80.5%、R2为79.7%,细胞外对比剂MRI R1为72.0%、R2为71.2%(R1 p=0.03;R2 p=0.01)。
- LR-5诊断肝细胞癌的敏感度:钆塞酸二钠MRI常规门静脉期R1为64.4%、R2为64.4%,细胞外对比剂MRI R1为72.0%、R2为71.2%(R1 p=0.03;R2 p=0.03)。
- LR-5诊断肝细胞癌的特异度:钆塞酸二钠MRI延迟门静脉期两名医师均为88.0%,细胞外对比剂MRI两名医师均为92.0%(p=0.31),钆塞酸二钠MRI常规门静脉期两名医师均为92.0%(p=0.31)。
临床应用与阅片要点
- 采用钆塞酸二钠MRI诊断肝细胞癌时,延迟门静脉期较常规门静脉期可提高LR-5的敏感度且特异度相当。
- 作者认为钆塞酸二钠MRI采用延迟门静脉期可能是诊断肝细胞癌的合适选择,其敏感度高于细胞外对比剂MRI且不损害特异度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the diagnostic performance of MRI with gadoxetate disodium (EOB-MRI) using conventional portal venous phase (CPVP) and late portal venous phase (LPVP) in the noninvasive diagnosis of hepatocellular carcinoma (HCC), with intraindividual comparison of MRI with extracellular contrast agent (ECA-MRI).
MATERIALS AND METHODS: This retrospective study included 107 prospectively enrolled at-risk patients (mean age, 59.4 years; 89 men) with 143 lesions (118 HCCs) who underwent both ECA-MRI and EOB-MRI using CPVP and LPVP. Two radiologists assessed all lesions using LI-RADS v2018. The per-lesion diagnostic performance was compared using generalized estimating equations.
RESULTS: In HCCs, nonperipheral washout appearance was less frequent on EOB-MRI using CPVP than on ECA-MRI (R1: 69.5 vs. 79.7%, p = 0.02; R2: 66.9 vs. 76.3%, p = 0.02), but more frequent on EOB-MRI using LPVP than on ECA-MRI (R1: 94.1 vs. 79.7%, p < 0.001; R2: 92.4 vs. 76.3%, p < 0.001). For LR-5, EOB-MRI using LPVP showed significantly higher sensitivity for diagnosing HCC than ECA-MRI (R1, 80.5 vs. 72.0%, p = 0.03; R2: 79.7 vs. 71.2%, p = 0.01), while EOB-MRI using CPVP showed significantly lower sensitivity than ECA-MRI (R1: 64.4 vs. 72.0%, p = 0.03; R2: 64.4 vs. 71.2%, p = 0.03). The specificity of EOB-MRI using LPVP (both Readers: 88.0%) did not differ significantly from that of ECA-MRI (both Readers: 92.0%, p = 0.31) or EOB-MRI using CPVP (both Readers: 92.0%, p = 0.31).
CONCLUSIONS: EOB-MRI using LPVP demonstrated higher sensitivity for HCC diagnosis than ECA-MRI and EOB-MRI using CPVP, while maintaining comparable specificity.
KEY POINTS: Question MRI with gadoxetate disodium (EOB-MRI) using the late portal venous phase (LPVP) for HCC diagnosis has not been directly compared with MRI with extracellular contrast agent (ECA-MRI). Findings EOB-MRI using LPVP improved the sensitivity of HCC diagnoses compared with ECA-MRI and EOB-MRI using conventional portal venous phase, without compromising specificity. Clinical relevance EOB-MRI using LPVP may be a suitable option for HCC diagnosis, demonstrating higher sensitivity than ECA-MRI without compromising specificity.
引用
- Jeong B, Han DH, Lee S, et al. Diagnosing HCC with conventional and late portal venous phase MRI: intraindividual comparison of MRI with extracellular contrast agent. Eur Radiol. 2025. PMID: 41136757. doi:10.1007/s00330-025-12082-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。